Amphastar Pharmaceuticals Profit Margin

The latest profit margin for AMPH is 10.76% as of June 2026. That compares with 18.7% in the prior-year period — down 42.5% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Amphastar Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMPH's profit margin moved from 18.7% to 10.76% — a 42.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amphastar Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, AMPH currently prints 10.76% for profit margin, while the sector average sits near 13.89%. That is roughly 22.6% below the sector mean. Large gaps often invite a closer look at Amphastar Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Amphastar Pharmaceuticals converts resources into returns. At 10.76%, AMPH may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 18.7% in the prior-year period — down 42.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AMPH's profit margin (10.76%), review year-over-year change from 18.7%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.